title: An efficacy trial of a mammalian cell-derived recombinant DNA hepatitis B vaccine in infants born to mothers positive for HBsAg, in Shanghai, China.
abstract: We conducted a randomized, double-blind clinical trial of an experimental mammalian cell-derived DNA hepatitis B vaccine (Betagen, Connaught Laboratories Ltd, Toronto, Canada) to determine its efficacy in infants born to mothers who were carriers of hepatitis B surface antigen (HBsAg). Four groups of 55 infants received injections as follows: (1) a licensed plasma-derived vaccine (Lanzhou, Lanzhou Institute for Biological Products, Lanzhou, People's Republic of China), 20 micrograms; (2) Betagen, 20 micrograms; (3) Betagen, 20 micrograms+hepatitis B immune globulin (HBIG); and (4) Betagen, 10 micrograms+HBIG. Vaccine injections were given at birth and at 1 and 6 months and HBIG was given at birth. The vaccines were compared to a historical placebo control group. The efficacy of Betagen alone was 82.6% compared to 51.0% for the Lanzhou. Efficacy of Betagen increased with the concomitant use of HBIG. No infants who were HBsAg negative at birth and/or were born to hepatitis B e antigen (HBeAg) negative mothers became carriers. The rate of HBsAg in infants receiving Betagen alone, and born to mothers who were HBeAg positive, decreased from 60% at birth to 20% by the ninth month, compared to 62.5% and 50% (respectively) for Lanzhou. The percentage of infants with protective levels of antiHBs was significantly higher for Betagen alone than for Lanzhou, but the geometric mean titre of antiHBs for responders was not significantly different. We have shown that Betagen alone is highly efficacious in preventing the development of hepatitis B in infants born to mothers who are carriers of HBsAg and is also highly effective in reducing the carriage of HBsAg in infants who are HBsAg positive at birth and/or born to HBeAg positive mothers.
authors.affiliation: Department of Preventive Medicine and Biostatistics, Faculty of Medicine, University of Toronto, Ontario, Canada.
authors.forename: M L
authors.initials: ML
authors.lastname: Halliday
authors.forename: L Y
authors.initials: LY
authors.lastname: Kang
authors.forename: J G
authors.initials: JG
authors.lastname: Rankin
authors.forename: R A
authors.initials: RA
authors.lastname: Coates
authors.forename: P N
authors.initials: PN
authors.lastname: Corey
authors.forename: Z H
authors.initials: ZH
authors.lastname: Hu
authors.forename: T K
authors.initials: TK
authors.lastname: Zhou
authors.forename: G J
authors.initials: GJ
authors.lastname: Yuan
authors.forename: F L
authors.initials: FL
authors.lastname: Yao
mesh_terms: D002353:Carrier State / Q000276:immunology; D002681:China; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000517:prevention & control*; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D014614:Vaccines, Synthetic; D014761:Viral Hepatitis Vaccines
chemical_list: D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic; D014761:Viral Hepatitis Vaccines